K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Gene. 2021 Aug 15;793:145747. doi: 10.1016/j.gene.2021.145747. Epub 2021 May 30.
In addition to being a tumour suppressor, TP53 is a suppressor of inflammation, and dysfunction of this gene has been related to autoimmune diseases. Patients with autoimmunity, such as rheumatoid arthritis (RA) have an increased risk of certain cancers, like lymphomas, indicating that some underlying mechanisms may modulate risk of both cancers and autoimmunity.
We genotyped 5 common genetic variants in TP53 and its main regulators MDM2 and MDM4 in a sample of 942 RA patients and 3,747 healthy controls, and mined previously published GWAS-data, to assess the potential impact of these variants on risk of RA.
For the TP53 Arg72Pro polymorphism (rs1042522), MDM4 SNP34091 (rs4245739) and MDM2 SNP285C (rs117039649), we found no association to risk of RA. For MDM2 SNP309 (rs2279744), the minor G-allele was associated with a reduced risk of RA (OR: 0.87; CI: 0.79-0.97). This association was also seen in genotype models (OR: 0.86; CI: 0.74-0.99 and OR: 0.79; CI 0.63-0.99; dominant and recessive model, respectively), but was not validated in a large GWAS data set. For MDM2 del1518 (rs3730485), the minor del-allele was associated with an increased risk of RA in the dominant model (OR: 1.18; CI: 1.02-1.38). Stratifying RA cases and controls into phylogenetic subgroups according to the combined genotypes of all three MDM2 polymorphism, we found individuals with the del158-285-309 genotype del/ins-G/G-T/T to have an increased risk of RA as compared to those with the ins/ins-G/G-G/G genotype (OR: 1.56; CI: 1.18-2.06) indicating opposite effects of the del1518 del-allele and the SNP309 G-allele.
We find a potential association between the MDM2 del1518 variant and RA, and indications that combinatorial genotypes and haplotypes in the MDM2 locus may be related to RA.
TP53 不仅是一种肿瘤抑制基因,还是炎症的抑制剂,该基因功能障碍与自身免疫性疾病有关。患有自身免疫性疾病(如类风湿关节炎(RA))的患者患某些癌症(如淋巴瘤)的风险增加,这表明某些潜在机制可能调节癌症和自身免疫性疾病的风险。
我们在 942 例 RA 患者和 3747 例健康对照者的样本中对 TP53 及其主要调节因子 MDM2 和 MDM4 的 5 个常见遗传变异进行了基因分型,并挖掘了先前发表的 GWAS 数据,以评估这些变异对 RA 风险的潜在影响。
对于 TP53 Arg72Pro 多态性(rs1042522)、MDM4 SNP34091(rs4245739)和 MDM2 SNP285C(rs117039649),我们未发现它们与 RA 风险相关。对于 MDM2 SNP309(rs2279744),次要 G 等位基因与 RA 风险降低相关(OR:0.87;95%CI:0.79-0.97)。该关联也见于基因型模型(OR:0.86;95%CI:0.74-0.99 和 OR:0.79;95%CI 0.63-0.99;分别为显性和隐性模型),但在大型 GWAS 数据集未得到验证。对于 MDM2 del1518(rs3730485),次要 del 等位基因与 RA 风险增加相关(OR:1.18;95%CI:1.02-1.38)。根据三个 MDM2 多态性的组合基因型,将 RA 病例和对照分为进化亚群,我们发现与具有 del158-285-309 基因型 del/ins-G/G-T/T 的个体相比,具有 del1518del 等位基因和 SNP309 G 等位基因的个体患 RA 的风险增加(OR:1.56;95%CI:1.18-2.06),表明 MDM2 del1518 变异与 RA 之间存在潜在关联,并且 MDM2 基因座中的组合基因型和单倍型可能与 RA 有关。